Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone Acetonide Adjunctive to Verteporfin in Neovascular AMD
NCT00148551Phase 3Unknown
- Sponsor
- Canadian Retinal Trials Group
- Start
- Jan 2004
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of triamcinolone acetonide in age-related macular degeneration (AMD), sponsored by Canadian Retinal Trials Group. Status: unknown.
02
Drugs
triamcinolone acetonide
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00148551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148551.